Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01076764 · ClinicalTrials.gov registry record · Phase 3
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,220
- Enrollment target
NCT01076764: Completed Phase 3 study, sponsored by Sanofi.
NCT01076764 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 13,220 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1615% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01076764, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,220 participants
- Enrollment target
Study Summary
Primary Objective: * To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide Secondary Objectives: * To demonstrate the superior efficacy (composite of all-cause death + MI + any stroke) of Otamixaban as compared to UFH + Eptifibatide * To document the effect of Otamixaban on rehospitalization or prolongation of hospitalization due to a new episode of myocardial ischemia/myocardial infarction as compared to UFH + eptifibatide * To document the effect on mortality (all cause death) of Otamixaban as compared to UFH + eptifibatide * To document the safety of Otamixaban as compared to UFH + eptifibatide * To document the effect of Otamixaban on thrombotic procedural complications during the index Percutaneous Coronary Intervention (PCI) as compared to UFH + eptifibatide
Interventions
- DRUG Eptifibatide
- DRUG Otamixaban
- DRUG Placebo (for Otamixaban)
- DRUG UFH
- DRUG Placebo (for UFH)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,220 participants |
| Start Date | 2010-04 |
| Est. Completion | 2013-05 |
| Phase | Phase 3 |
What the finished NCT01076764 record still lists
NCT01076764 is an interventional study that assigns participants to a tested intervention. Its 13,220 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1615% higher).
The record links to 0 conditions, and to 5 interventions - of which Eptifibatide is the first listed.
NCT01076764 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01076764 about?
NCT01076764 is a clinical study titled "Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy". Primary Objective: * To demonstrate the superior efficacy (composite of all-cause death + Myocardial Infarction (MI)) of Otamixaban to Unfractionated Heparin (UFH) + Eptifibatide Secondary Objectives: * To demonstrate the superior efficacy (composite of all-cause death + MI + any stroke) of Otami...
What is the current status of trial NCT01076764?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,220 participants. The study started on 2010-04. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01076764?
The interventions under investigation include: Eptifibatide (DRUG), Otamixaban (DRUG), Placebo (for Otamixaban) (DRUG), UFH (DRUG), Placebo (for UFH) (DRUG).
Who is sponsoring clinical trial NCT01076764?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01076764's enrollment target sits among peer trials
13,220 17th of 2000 higher than 1,984 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05141396 · 13,400 participants · NA
Telehealth-Enabled, Real-time Audit and Feedback for Clinician AdHerence (TEACH)
- NCT05991453 · 13,000 participants · NA
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
- NCT07177352 · 13,000 participants · Phase 3
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- NCT07028398 · 12,990 participants · NA
CMSL Ambulatory Sensitive Condition Nudge Study 2
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia